

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Daridorexant for treating insomnia disorder [ID3774]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- At the scoping workshop it was discussed that access to cognitive behavioural therapy for insomnia (CBT-I) varies by region. Stakeholders noted that if the recommendation for daridorexant stated that it must be used in addition to or after CBT-I, that could increase health inequalities. However, it was also noted that the clinical trials for daridorexant included people who did and who did not use CBT-I.
- The prevalence of insomnia is between 1.5 and 2 times higher in women than men.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- The committee may need to consider the availability of CBT-I when making its recommendation for daridorexant.
- Issues relating to differences in prevalence or incidence cannot be addressed in a technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Richard Diaz **Date:** 25/4/2022